The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
Are there any particular multiple sclerosis trials that you’re keeping an eye on?The field of MS is exciting. We’ve gone from having zero disease-modifying therapies in 1992, to our first medication in 1993, to, now, having 17 separate products. It’s amazing the leap forward. We now have 14 branded products, we have 2 unbranded generics, and 1 branded generic. That’s an amazing leap forward. That’s faster than anything in neurology, and frankly, faster than most things in medicine.
Click the above banner to listen to Dr. Kantor’s response